| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2022―Oct―29 |
National trends in buprenorphine prescribing before and during the COVID-19 pandemic |
Mir M. Ali, Timothy B. Creedon, Laura Jacobus-Kantor, Tisamarie B. Sherry |
| 2 |
[GO] |
2022―Oct―28 |
A cohort study examining changes in treatment patterns for alcohol use disorder among commercially insured adults in the United States during the COVID-19 pandemic |
Alisa B. Busch, Ateev Mehrotra, Shelly F. Greenfield, Lori Uscher-Pines, Sherri Rose, Haiden A. Huskamp |
| 3 |
[GO] |
2022―Oct―04 |
Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic |
Kevin A. Hallgren, James Darnton, Sean Soth, Kendra L. Blalock, Alyssa Michaels, Paul Grekin, Andrew J. Saxon, Steve Woolworth, Judith I. Tsui |
| 4 |
[GO] |
2022―May―08 |
Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis |
Kim A. Hoffman, Canyon Foot, Ximena A. Levander, Ryan Cook, Javier Ponce Terashima, John W. McIlveen, P. Todd Korthuis, Dennis McCarty |
| 5 |
[GO] |
2022―Mar―25 |
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic |
Kristin M. Mattocks, David T. Moore, Dora Lendvai Wischik, Christina M. Lazar, Marc I. Rosen |
| 6 |
[GO] |
2022―Jan―22 |
The impact of COVID-19 on health care professionals who are exposed to drug-related deaths while supporting clients experiencing addiction |
Daniel O'Callaghan, Sharon Lambert |
| 7 |
[GO] |
2021―Dec―08 |
Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia |
Treah Haggerty, Maryam Khodaverdi, Patricia Dekeseredy, Nathan Wood, Brian Hendricks, Jason Peklinsky, Cara L. Sedney |
| 8 |
[GO] |
2021―Nov―04 |
“No home to take methadone to”: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston |
Miriam T.H. Harris, Audrey M. Lambert, Ariel D. Maschke, Sarah M. Bagley, Alexander Y. Walley, Christine M. Gunn |
| 9 |
[GO] |
2021―Oct―30 |
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19 |
Robert Rosales, Tim Janssen, Julia Yermash, Kimberly R. Yap, Elizabeth L. Ball, Bryan Hartzler, Bryan R. Garner, Sara J. Becker |
| 10 |
[GO] |
2021―Oct―28 |
A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic |
Chinazo O. Cunningham, Laila Khalid, Yuting Deng, Kristine Torres-Lockhart, Mariya Masyukova, Shenell Thomas, Chenshu Zhang, Tiffany Lu |
| 11 |
[GO] |
2021―Oct―22 |
“How can I hug someone now [over the phone]?”: Impacts of COVID-19 on peer recovery specialists and clients in substance use treatment |
Morgan S. Anvari, C.J. Seitz-Brown, Jessie Spencer, Megan Mulheron, Sara Abdelwahab, Christina P.C. Borba, Jessica F. Magidson, Julia W. Felton |
| 12 |
[GO] |
2021―Aug―06 |
Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year |
Gavin Bart, Solvejg Wastvedt, James S. Hodges, Rebecca Rosenthal |
| 13 |
[GO] |
2021―Jul―21 |
SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups |
Peter J. Kelly, Kim McCreanor, Alison K. Beck, Isabella Ingram, Darren O'Brien, Angie King, Ryan McGlaughlin, Angela Argent, Mark Ruth, Bendt Skjold Hansen, Ditlev Andersen, Victoria Manning, Anthony Shakeshaft, Leanne Hides, Briony Larance |
| 14 |
[GO] |
2021―Jun―26 |
The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth |
Richard H. Cales, Shannon C. Cales, Jacob Shreffler, Martin R. Huecker |
| 15 |
[GO] |
2021―Jun―25 |
COVID-19 related substance use services policy changes: Policymaker perspectives on policy development & implementation |
Brandy F. Henry, Aimee Campbell, Timothy Hunt, Jessica K. Johnson, Amar D. Mandavia, Michael Chaple, Caroline Arout, Elwin Wu, Harold A. Pincus, Edward V. Nunes, Pat Lincourt, Frances R. Levin, Nabila El-Bassel |
| 16 |
[GO] |
2021―Jun―24 |
Changes in methadone take-home dosing before and after COVID-19 |
Ofer Amram, Solmaz Amiri, Emily L. Thorn, Robert Lutz, Paul J. Joudrey |
| 17 |
[GO] |
2021―Jun―24 |
The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives |
Chunqing Lin, Sarah E. Clingan, Sarah J. Cousins, Jonathan Valdez, Larissa J. Mooney, Yih-Ing Hser |
| 18 |
[GO] |
2021―May―31 |
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms |
Peter C. Treitler, Cadence F. Bowden, James Lloyd, Michael Enich, Amesika Nyaku, Stephen Crystal |
| 19 |
[GO] |
2021―May―18 |
Corrigendum to “Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study” [Journal of Substance Abuse Treatment 129 (2021) 108374] |
Cayley Russell, Farihah Ali, Frishta Nafeh, Jürgen Rehm, Sean LeBlanc, Tara Elton-Marshall |
| 20 |
[GO] |
2021―Apr―29 |
Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19 |
Sarah Brothers, Adam Viera, Robert Heimer |
| 21 |
[GO] |
2021―Apr―29 |
Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects |
Bradley M. Buchheit, Haven Wheelock, Abby Lee, Kimberly Brandt, Jessica Gregg |
| 22 |
[GO] |
2021―Apr―09 |
The new services that opioid treatment programs have adopted in response to COVID-19 |
Jonathan Cantor, Agustina Laurito |
| 23 |
[GO] |
2021―Apr―09 |
The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here? |
Kathlene Tracy, Leah Wachtel, Teri Friedman |
| 24 |
[GO] |
2021―Apr―09 |
How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic |
Jesse M. Pines, Mark S. Zocchi, Bernard S. Black, Jestin N. Carlson, Pablo Celedon, Ali Moghtaderi, Arvind Venkat |
| 25 |
[GO] |
2021―Apr―08 |
Adaptations to Indiana's 21st Century Cures-funded recovery coaching initiative in the wake of COVID-19 |
Monte D. Staton, Dennis P. Watson, Lisa Robison Taylor, Noah Tye |
| 26 |
[GO] |
2021―Apr―08 |
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder |
Colleen B. Mistler, Matthew C. Sullivan, Michael M. Copenhaver, Jaimie P. Meyer, Alexis M. Roth, Sheela V. Shenoi, E. Jennifer Edelman, Jeffrey A. Wickersham, Roman Shrestha |
| 27 |
[GO] |
2021―Apr―08 |
Impact of COVID-19 on service delivery for an evidence-based behavioral treatment for families involved in the child welfare system |
Gracelyn Cruden, Mark Campbell, Lisa Saldana |
| 28 |
[GO] |
2021―Apr―08 |
Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic |
Jonathan Cantor, Andrew W. Dick, Rebecca Haffajee, Megan F. Pera, Dena M. Bravata, Bradley D. Stein, Christopher Whaley |
| 29 |
[GO] |
2021―Apr―08 |
Research on substance use disorders during the COVID-19 pandemic |
Nora D. Volkow, Carlos Blanco |
| 30 |
[GO] |
2021―Mar―23 |
Addressing cigarette smoking cessation treatment challenges during the COVID-19 pandemic with social media |
Meredith C. Meacham, Erin A. Vogel, Johannes Thrul, Danielle E. Ramo, Derek D. Satre |
| 31 |
[GO] |
2021―Mar―20 |
Identifying the Impacts of the COVID-19 Pandemic on Service Access for People who Use Drugs (PWUD): A National Qualitative Study |
Cayley Russell, Farihah Ali, Frishta Nafeh, Jürgen Rehm, Sean LeBlanc, Tara Elton-Marshall |
| 32 |
[GO] |
2021―Mar―20 |
Recovering from substance use disorder during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City |
Emily A. Hurley, Kimberly Piña, Victoria Cegielski, Janelle R. Noel-MacDonnell, Melissa K. Miller |
| 33 |
[GO] |
2021―Feb―11 |
Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic |
Michael Kidorf, Robert K. Brooner, Kelly E. Dunn, Jessica M. Peirce |
| 34 |
[GO] |
2021―Jan―26 |
Telemedicine works for treating substance use disorder: The STAR clinic experience during COVID-19 |
Leah Fiacco, Brenda L. Pearson, Robyn Jordan |
| 35 |
[GO] |
2021―Jan―20 |
Using Telehealth to Improve Buprenorphine Access During and After COVID-19: A Rapid Response Initiative in Rhode Island |
Seth A. Clark, Elizabeth A. Samuels, Rachel S. Wightman, Caroline Wunsch, Lee Ann Jordison Keeler, Neha Reddy, Corey Davis |
| 36 |
[GO] |
2021―Jan―18 |
Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic |
Linda Wang, Jeffrey Weiss, Elizabeth Bogel Ryan, Justine Waldman, Stacey Rubin, Judy L. Griffin |
| 37 |
[GO] |
2021―Jan―13 |
Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study |
Sarah B. Hunter, Alex R. Dopp, Allison J. Ober, Lori Uscher-Pines |
| 38 |
[GO] |
2021―Jan―08 |
Adaptations to substance use disorder monitoring by physician health programs in response to COVID-19 |
Alexis Polles, Christopher Bundy, William Jacobs, Lisa J. Merlo |
| 39 |
[GO] |
2021―Jan―08 |
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19 |
Mary C. Figgatt, Zach Salazar, Elizabeth Day, Louise Vincent, Nabarun Dasgupta |
| 40 |
[GO] |
2021―Jan―08 |
A Collision of Crises: Addressing an HIV Outbreak among People who Inject Drugs in the midst of COVID-19 |
Jessica L. Taylor, Glorimar Ruiz-Mercado, Heather Sperring, Angela R. Bazzi |
| 41 |
[GO] |
2021―Jan―08 |
Increased HIV testing in people who use drugs hospitalized in the first wave of the COVID-19 pandemic |
Julia Zubiago, Meghan Murphy, Rubeen Guardado, Denise Daudelin, Dustin Patil, Alysse Wurcel |
| 42 |
[GO] |
2021―Jan―02 |
Integrated substance use and prenatal care delivery in the era of COVID-19 |
Elizabeth W. Patton, Kelley Saia, Michael D. Stein |
| 43 |
[GO] |
2020―Dec―28 |
Substance use treatment in Appalachian Tennessee amid COVID-19: Challenges and preparing for the future |
Satish K. Kedia, Michael Schmidt, Patrick J. Dillon, Hassan Arshad, Xinhua Yu |
| 44 |
[GO] |
2020―Dec―27 |
Sharp Decline in Hospital and Emergency Department Initiated Buprenorphine for Opioid Use Disorder During COVID-19 State of Emergency in California |
Andrew A. Herring, Mariah Kalmin, Melissa Speener, David Goodman-Meza, Hannah Snyder, Arianna Sampson, Aimee Moulin, Steve Shoptaw |
| 45 |
[GO] |
2020―Dec―27 |
Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder |
Kristi Lynn Stringer, Kirsten J. Langdon, Michelle McKenzie, Brad Brockmann, Phillip Marotta |
| 46 |
[GO] |
2020―Dec―17 |
Impacts of COVID-19 on residential treatment programs for substance use disorder |
A. Pagano, S. Hosakote, K. Kapiteni, E. Straus, J. Wong, J. Guydish |
| 47 |
[GO] |
2020―Dec―13 |
A chance to do it better: Methadone maintenance treatment in the age of Covid-19 |
David Frank |
| 48 |
[GO] |
2020―Dec―11 |
Addressing a rapidly changing service landscape during the COVID-19 pandemic: Creation of the Oregon substance use disorder resource collaborative |
Rachel A. Lockard, Kelsey C. Priest, Patrick C.M. Brown, Amanda Graveson, Honora Englander |
| 49 |
[GO] |
2020―Dec―11 |
COVID-19 surveillance and Black American substance use disorder: An examination of data and policy |
Vanessa Miller |
| 50 |
[GO] |
2020―Dec―05 |
Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives |
Mary A. Hatch-Maillette, K. Michelle Peavy, Judith I. Tsui, Caleb J. Banta-Green, Stephen Woolworth, Paul Grekin |
| 51 |
[GO] |
2020―Dec―04 |
With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic |
Matthew W. Courser, Holly Raffle |
| 52 |
[GO] |
2020―Dec―03 |
Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19 |
Giliane Joseph, Kristine Torres-Lockhart, Melissa R. Stein, Pamela Mund, Shadi Nahvi |
| 53 |
[GO] |
2020―Dec―03 |
Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19 |
Nicholas A. Livingston, Victoria Ameral, Anne N. Banducci, Risa B. Weisberg |
| 54 |
[GO] |
2020―Dec―03 |
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges |
Shalini Arunogiri, Nicholas Lintzeris |
| 55 |
[GO] |
2020―Dec―03 |
Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response |
Amy McDonnell, Courtney MacNeill, Brittany Chapman, Nicole Gilbertson, Megan Reinhardt, Stephanie Carreiro |
| 56 |
[GO] |
2020―Dec―03 |
COVID-19: Broadening the horizons of U.S. harm reduction practices through managed alcohol programs |
Nicky J. Mehtani, Jessica T. Ristau, Joanna Eveland |
| 57 |
[GO] |
2020―Dec―02 |
The use of mindfulness dialogue for life in substance use disorder treatment in the time of COVID-19 |
Diane J. Abatemarco, Meghan Gannon, Dennis J. Hand, Vanessa L. Short, Kimberly McLaughlin, Daniel Martin |
| 58 |
[GO] |
2020―Dec―02 |
COVID-19 and treating incarcerated populations for opioid use disorder |
Christopher J. Donelan, Edmond Hayes, Ruth A. Potee, Levin Schwartz, Elizabeth A. Evans |
| 59 |
[GO] |
2020―Nov―24 |
A delicate compromise: Striking a balance between public safety measures and the psychosocial needs of staff and clients in residential substance use disorder treatment amid COVID-19 |
Ashleigh Herrera |
| 60 |
[GO] |
2020―Nov―24 |
Adolescent substance use: Challenges and opportunities related to COVID-19 |
Dana Sarvey, Justine W. Welsh |
| 61 |
[GO] |
2020―Nov―24 |
Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19 |
Max Jordan Nguemeni Tiako |
| 62 |
[GO] |
2020―Nov―24 |
Telehealth sustains patient engagement in OUD treatment during COVID-19 |
James R. Langabeer, Andrea Yatsco, Tiffany Champagne-Langabeer |
| 63 |
[GO] |
2020―Nov―24 |
Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic |
Kelly E. Dunn, Robert K. Brooner, Kenneth B. Stoller |
| 64 |
[GO] |
2020―Nov―22 |
Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders |
Sara J. Becker, Bryan R. Garner, Bryan J. Hartzler |
| 65 |
[GO] |
2020―Nov―21 |
Socially distant and out of reach: Unintended consequences of COVID-19 prevention efforts on transgender and gender non-binary populations in Puerto Rico |
Kyle Melin, Darlene Santiago Quiñones, Carlos E. Rodríguez-Díaz |
| 66 |
[GO] |
2020―Nov―17 |
Caring for women with substance use disorders through pregnancy and postpartum during the COVID-19 pandemic: Lessons learned from psychology trainees in an integrated OBGYN/substance use disorder outpatient treatment program |
Jaclyn S. Sadicario, Anna Beth Parlier-Ahmad, Julia K. Brechbiel, Leila Z. Islam, Caitlin E. Martin |
| 67 |
[GO] |
2020―Nov―14 |
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade? |
Edward V. Nunes, Frances R. Levin, Muredach P. Reilly, Nabila El-Bassel |
| 68 |
[GO] |
2020―Nov―04 |
COVID-19 highlights the pitfalls of reliance on the carceral system as a response to addiction |
Melissa J. Zielinski, Kendra E. Hinton, Chelsey E. Bull |
| 69 |
[GO] |
2020―Oct―21 |
“I have to be around people that are doing what I’m doing”: The importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities |
Mary B. Kleinman, Julia W. Felton, Andre Johnson, Jessica F. Magidson |
| 70 |
[GO] |
2020―Oct―21 |
COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange |
Rolando Tringale, Andrew M. Subica |
| 71 |
[GO] |
2020―Oct―21 |
A commentary on the impact of COVID-19 on engagement of youth with substance use and co-occurring psychiatric disorders |
Sarah M. Bagley, Scott E. Hadland, Amy Yule |
| 72 |
[GO] |
2020―Oct―21 |
Healthcare Utilization Patterns among Persons Who Use Drugs During the COVID-19 Pandemic |
Sean M. Murphy, James Yoder, Jyotishman Pathak, Jonathan Avery |
| 73 |
[GO] |
2020―Oct―21 |
COVID-19-related treatment service disruptions among people with single- and polysubstance use concerns |
Alexandra M. Mellis, Marc N. Potenza, Jessica N. Hulsey |
| 74 |
[GO] |
2020―Oct―10 |
Rapid Transitional Reponse to the COVID-19 Pandemic by Opioid Agonist Treatment Programs in Ukraine |
Anna Meteliuk, Samy Galvez, Lynn M. Madden, Iryna Pykalo, Tanya Fomenko, Myroslava Fillipovich, Scott O. Farnum, Sergii Dvoryak, Zahedsul Islam, Frederick L. Altice |
| 75 |
[GO] |
2020―Oct―09 |
Virtual reality for behavioral health workforce development in the era of COVID-19 |
Sara Becker, Michael Chaple, Tom Freese, Holly Hagle, Maxine Henry, Igor Koutsenok, Laurie Krom, Rosemarie Martin, Todd Molfenter, Kristen Powell, Nancy Roget, Laura Saunders, Isa Velez, Ruth Yanez |
| 76 |
[GO] |
2020―Oct―09 |
The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19 |
Jaclyn M.W. Hughto, Lisa Peterson, Nicholas S. Perry, Alex Donoyan, Matthew J. Mimiaga, Kimberly M. Nelson, David W. Pantalone |
| 77 |
[GO] |
2020―Oct―09 |
Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada |
Dennis C. Wendt, Stéphanie Marsan, Daniel Parker, Karen E. Lizzy, Jessica Roper, Christopher Mushquash, Kamilla L. Venner, Alice Lam, Jennifer Swansburg, Nancy Worth, Nicholas Sorlagas, Tania Quach, Kristapore Manoukian, Payton Bernett, Sandra M. Radin |
| 78 |
[GO] |
2020―Oct―08 |
Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic |
Alexandra Duncan, Noah Sanders, Maria Schiff, Tyler N.A. Winkelman |
| 79 |
[GO] |
2020―Oct―06 |
A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose |
Benjamin P. Linas, Alexandra Savinkina, Carolina Barbosa, Peter P. Mueller, Magdalena Cerdá, Katherine Keyes, Jagpreet Chhatwal |
| 80 |
[GO] |
2020―Oct―05 |
Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic |
Jarratt D. Pytell, Darius A. Rastegar |
| 81 |
[GO] |
2020―Oct―04 |
Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond |
Brandon G. Bergman, John F. Kelly |
| 82 |
[GO] |
2020―Oct―04 |
Considerations for remote delivery of behavioral economic interventions for substance use disorder during COVID-19 and beyond |
Lara N. Coughlin, Erin E. Bonar, Warren K. Bickel |
| 83 |
[GO] |
2020―Oct―04 |
COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings |
Laura MacKinnon, M. Eugenia Socías, Geoff Bardwell |
| 84 |
[GO] |
2020―Oct―03 |
Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care? |
Joan Trujols, Antonio Larrabeiti, Oriol Sànchez, Maite Madrid, Sandra De Andrés, Santiago Duran-Sindreu |
| 85 |
[GO] |
2020―Oct―02 |
Providing addiction services during a pandemic: Lessons learned from COVID-19 |
Bruce S. Liese, Corey M. Monley |
| 86 |
[GO] |
2020―Sep―25 |
Substance use disorder treatment, parenting, and COVID-19 |
Camille C. Cioffi, Leslie D. Leve |
| 87 |
[GO] |
2020―Sep―25 |
Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency |
Kevin Wenzel, Marc Fishman |
| 88 |
[GO] |
2020―Sep―25 |
Access to Substance Use Disorder Treatment During COVID-19: Implications from Reduced Local Jail Populations |
Erkmen G. Aslim, Murat C. Mungan |
| 89 |
[GO] |
2020―Sep―21 |
COVID-19: Revising our attitudes toward agonist medications and their diversion |
Brandon del Pozo, Josiah D. Rich |
| 90 |
[GO] |
2020―Sep―18 |
Treatment experience for opioid use disorder during COVID-19 in India: Learning from patients |
Prabhat Mani Pandit, Gayatri Bhatia, Siddharth Sarkar |
| 91 |
[GO] |
2020―Aug―30 |
Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine |
Lori Uscher-Pines, Jessica Sousa, Pushpa Raja, Ateev Mehrotra, Michael Barnett, Haiden A. Huskamp |
| 92 |
[GO] |
2020―Aug―12 |
Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities |
Simeon D. Kimmel, Angela R. Bazzi, Joshua A. Barocas |
| 93 |
[GO] |
2020―Aug―11 |
Adaptation of Contingency Management for Stimulant Use Disorder During the COVID-19 Pandemic |
Evelyn Zastepa, Jane C. Sun, Jennifer Clune, Nickie Mathew |
| 94 |
[GO] |
2020―Aug―05 |
Making lemonade from SARS coronavirus-2 lemons: Transitioning a smoking cessation trial to a virtual platform |
Martin C. Mahoney, Rebecca Ashare, Nicolas Schlienz, CeCe Duerr, Larry W. Hawk |
| 95 |
[GO] |
2020―Aug―01 |
Sheltering in place and social distancing when the services provided are housing and social support: The COVID-19 health crisis and recovery housing |
Amy A. Mericle, Dave Sheridan, Jason Howell, George S. Braucht, Katherine Karriker-Jaffe, Douglas L. Polcin |
| 96 |
[GO] |
2020―Jul―25 |
Editorial: COVID-19 and its impact on SUD treatment |
Peter D. Friedmann, Amanda Abraham, Elizabeth Evans, Joseph Glass, Mark Ilgen, LaTrice Montgomery |
| 97 |
[GO] |
2020―May―07 |
Call for commentaries on COVID-19 |
|
